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Gemfibrozil, a hypolipidemic drug mainly used in the treatment of hypertriglyceridemie states, strongly inhibits the rat hepatic microsomal fatty 
acid chain elongation system in vitro. The inhibition i5 independent on the reducing cofactor used in the assay. Furthermore. gemfibrozil seems 
to act by inhibiting the rate-limiting step of the elongation process, the condensing reaction, without discriminating among the proposed three 
different condensing enzymes, devoted to condensation of saturated, mono*unsaturated and polyunsaturated acyl-CoA substrates. 
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!. INTRODUCTION 
The microsomal fatty acid chain elongation system, 
in concert with desaturases, leads to the formation of 
long-chain poly-unsaturated fatty aci,~s. Che general 
mechanism of microsomal fatty acid elongation in- 
volves the sequential activities of four enzymes: ( ! ) the 
condensing enzyme, the rate-limiting step o1" the whole 
system; (2) fl-ketoaeyl-CoA reduetase; (3) fl-hydro- 
xyacyl-CoA dehydrase; and (4) trans-2-enoyI-CoA 
reductase [1]. Although the biochemical properties of 
the hepatic microsomal elongation system have been 
studied extensively [2,3], little is known about the effects 
of xenobioties on this system [4]. 
Gemfibrozil is a widely used hypolipidemic drug. 
mainly in hypertriglyceridemic states. Generally clas- 
sified as a fibric acid derivative, it exhibits different 
pharmacological properties from other related drugs. 
Gemfibrozil stimulates triglyceride-rich lipoprotein 
clearance, decreases hepatic VLDL prodt"rtion and in- 
creases HDL-cholesterol levels [5]. Nevertheless. the 
fundamental mechanism of action of gemfibrozil is not 
well established. The quality of fatty acids (chain length 
and number of unsaturations), either in the free form or 
incorporated into glycerolipids, plays an important role 
controlling lipoprotcin metabolism [6]. We thus aimed 
to test the effect of gemfibrozil on enzymes related to the 
hepatic fatty acids synthesis. As a part of this project. 
we have studied the in vitro effect of gemfibrozil on 
microsomal fatty acid chain elongation. 
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2. MATERIALS AND METHODS 
2.1. Chemicals 
Malonyl-CoA. palmitoyI-CoA (16:0 CoA), palmitoleoyl-CoA (9- 
16:1 CoAl. r-linolenie acid (6,9,12*18:3). NAD(P)H. fatty acid free 
albumin, rotenone, CoA and Tdzma were obtained from Sigma (S~. 
Louis. MO. USA). [2-~C]malonyI-CoA 150 mCi/mmol) was pur- 
chased from New England Nudcar (Boston. MA. USA). Scharlau Co 
136 liquid seintillation fluid was from Schar]au Co. (Barcelona. Spain) 
and gemfibrozi] was a generous gift from Lab, Parke-Davis {Bar- 
celona, Spain). General chemicals were obtained from commercial 
sources and were of analytical grade. 
2.2. Isolation oJmic~osmnes 
Male Spragoc Dawley rats ( 180-200 g) were maintained instarva- 
tion for __.4 h and then refed with a high carbohydrate fat-free diet IFat 
Free Diet U.S. Biochemical Corporation. Cleveland. OH. USAI for 
48 h. The animals were Ihen killed by decapitation between 8 and 9 
a.m. Liv~:.s were removed and perfused with ice-cold NaCI 0.q%. to 
remove contaminating haemoglobin. The tissue was homogenL,.ed in
ice-cold 0.25 M sucrose. 50 mM Trls-HCI buffer, pH 74~ and micro- 
saints were obtained as described previously, [7]. P;olein was deter- 
mined by the method of Bradford. using BSA as stand'~'~ r ]. 
2.3. S.vnthe.~is of r-linoh,,oyI-CoA 
The CoA derivative of r-linoleaic acid was prepared by the mixed 
anhydride procedure as described by Fang and Schulz [9]. and purified 
as described by AI-Arif and Blecher [10]. The concentration of the 
synthesized r-linolenoyI-CoA was measured by the method of EIiman 
[! I]. after cleavage of the thioester bond with hydroxylamine. 
2.4. Micro,~-vma! cwu/en,~atwn aml total elungathm oJJut:y acids 
The assay of fatty acid microsomal endogenous elongation was 
performed by the measurement of he incorporation of2-~C] malan~,'l- 
CoA into endogenous acyI-CoAs, basically as described previously [4]. 
The assay medium contained, in final concentrations: 100 mM Tris- 
HCI, pH 7,4. 2.5 mM Mg('l:. 2.5 mM ATP. 500aM NAD(P)H. and 
250 flg,ml microsomal prt~tcm. ~ ier~fihr,',il was added from stock 
solutions adjusted to pH 8 8.5 with O. I N NaOH. The pH of the assa) 
m¢Oi~ro w;l~ no! moditi~! hy thi~ addJl .n After 5 rain preineubation 
at 37°C. the reaction ssas started b~ .lddhlg 25 ,aM malon:,'l.CoA 
tcol3l;tir~!Jl[: t~.037 ll(" [2-"C] m;d, mvl-('t~At. When NADH was used 
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~ .  ?..0~M rc~e~e ~t~e~ ~ to t~ as~3.' med~am. WIh~n 
m~.~m;.~ e~zmc~ ~ M$~l.. ~d  ATP ~tere cmilted fi,~r~a 
~ a~ 3"~_. 4D~M a~fl.CeA ~ ~_~t~_.and ~ mmtamr the~ 
~-~y ~ em ~ (.:,.~ ~ ~). . "n~ ~ ; o n  a~i-.,- 
~r~ f~ e~e ~ ~,r~ c~the ~ ~ wxzss, was 
~ from the a~ay ~ I~ a~ ~ aft" 5 rain intuition 
z,I ~ t h e ~  ~tzes lol[~a~ b$, ~ l t~ I nfl 1.5~ KOH in 
~t~m~I .  ~ by mq~a~.=t~ at 65"C fc~45 m6m. A f t~ m:i- 
~ 1.5} with k~-cokl 5 N HCL the free fatty acids ~ ' rc  
L I~ ah~e,~ wi~lh 3 ml ~ k,.~,~ 0 mi total volume). 
n~L,-r N, am:! after ~r,~,~ of 7 ml c~ r ~m~'~t~ mhmn~_ th~ 
_~"~,~-~  w~ ommmt ia a lkdkman I.S 1800 lkluid 
~* , '~  co~.  ~, t -= are lm~'~ at ~ p_:~C] matc~A- 
CoA" - ". - of ~ t  lm~o~ 
U~ ou~ ~y cz~;~s ,  the e~z~z~t;e activities ~ ~  
a~ emgea~ms fan~ ~ ~ and ~ were Inepor- 
to ~h~, amo~ml , o f ~  l;aol,~a ~ (up to 400 pL#ml) 
• .~l ~ere ~ar  for ~ h: ;~ lSm/n  
?._~. z~ ~t.t-m 
lC~ v~h~.,~ ~ ~ 95% ga~faka~e timils ~e  ca!cu~ted by 
m~ms of a ~ Dom-R~"  ~ ~ des/gr, zd 
follmring T=l~'~ ~ [i;-~ .Statistical comlx~,z.ons 
(ANOVA msO ~t~re performed by the EPISTAT computer prosram. 
3. RESULTS 
The activities for endot~mous fatty acid elongation 
~x're 0,76 nmol/min~mg in the presence of  NADH,  and 
1.0"/nmol/min/mg in the presence of NADPH, showing 
the well-known preference of  the etortgatioa system for 
NADPH as reducing cofactor [I,3]. The preincubafion 
of  micrommal protein with gemfibrozil for 5 rain 
caused inhibition of  the endogenous activity. The in- 
hibitory effe~:t was dependent on the drug concentration 
added, but independent of  the reducing cofactor u~ 
Cfable l).No significant difference was found between 
Tat~e |
Effect of ~emfib~t~z~! on ¢ndo:~ and ~nou~ I~tt.~ a~d chtan 
~-T ib~ m ~-~ 2. GemfibrozB tamm~t~o~ lefled t~--re from 
O~i to I raM. f _~ curve was obts i~ ~h ~ con~ntratkm pomp. 
du#ma~, ¢~h ~/m¢ w/Or m/~o~ from |g'o p~t~d m! livers, 
o:~f~ apM¢ ~mit.s ~uM~ 
F ~¢*,Lm~.tm~ NADH 0,~tJ 027-0.33 
Ekm~ou NAD~rl 026 02)  O.32 
f - ~  NADPH f~m~tr~4~,14~,A 0 g ¢~A60..22 
f~a!t~tcr~c~,)'bC~A 0,14 ~ 32 ~ ~7 
the ICs0 value obtained in the prcsem:¢ of  NADH or 
NADPH. 
The addition o f  exogenous acyl-CoAs further in- 
creased the NADPH elon~tion activities, thus obtain- 
ing values of  2.39 nmol/minlmg with palmltoyl-CoA as 
substrate~ 2.18 nmoFm|n/mg with palmitoleoyl-CoA 
and i_96 nmoFmin/mg with r-linolenoyl-CoA. Again, 
the preincubation of microsomal  protein wRh ggmfi- 
broz~ caused inlu'bition of  the exogenous NADPH de- 
pendent elongation activity. The inhibitory effect was 
always dependent on the gemiibrozil concentration 
added, but the iC~ values oblained (Table I) were very 
6milar. irrespoctive of the acyl-CoA used in the assay 
(no significant difference among the three IC5o values). 
Moreover. when endogenous and exogenous IC5o val- 
ues were pooled, no significant difference was found. 
When NADPH was omitted from *.he incubation 
medinm~ conde-~t ion activities were assayed. The val- 
ues obtained: 1.47 nmol/mln!mg with palmitoyl-CoA as 
substrate, 1.09 nmol/mirdmg with palmitoleoyl-CoA 
and 1.64 nmol/min/mg with r-linolenoyl-CoA, were 
always lower than the corresponding elongation values. 
given the feed-back inhibit/on ofthe condensing enzyme 
induced by the reaction product, the fl-ketoacyl-CoA 
derivative [2]. Table I shows the IC~o values for gemfi- 
bro-zil inhibition o f  the condensing enzymes acti'dties. 
As in the case of  elongation, the inhibitory effect was 
dependent on gemfibrozil concentration, but unrelated 
to the acyl-CoA used as substrate {no significant differ- 
ence). Moreover. when ICso values from condensation 
and NADPH exogenous elongation activities were 
analyzed together, no significant difference was ob- 
tained. 
4. DISCUSSION 
The endoplasmic reticulum of mammalian liver is 
able to catalyze the elongation of fatt~ acids. The e: ,iest 
way to assay this activity is to uetermine the so called 
endogenous elongation, in tlds si{,a,:~n. "he system 
~.  as subs~rates, the fatty acids presen* in p. ix ~ os~::t, al
membranes, activated to acyl-CoAs by the microsom~.l 
acyl-CoA synthetase, provided that exogenous ma- 
lonyl-CoA. ATP. and Mg are added. When the en- 
dog.enous elongatio, activity was assayed in the pres- 
ence of the hypolipidemic drag gemfibrozil, strong in- 
hibition was found. As shown in Table I. the inhibitory 
potency ofgemfibrozil was independent of the reducing 
cofactor used. NADPH or NADH. At this point, these 
~c~ults ¢~-Id ~ fitted to two hypotheses. (!) Gemfi- 
brozil inhibits the endogenous elongation by acting on 
the rate-limiting strp of th~ system, the condensing en. 
zyw~ [~. As '.he con~kmsing r~aclion l~tv,'ccn the acyl- 
CoA and malonyl-CoA is the imfial ~tc~p in [he elonga- 
tion praters, and ~ not dep~ce. l  on red~-ing factors. 
lhi~ hypot~L~ cou ld  e~p~ain the simikifity b~tweCn lh¢ 
~v-~ IC~, vMu¢~ obtamrd ~cither vAth NADH or 
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NADPH). (2) Gemfibrozd could inhibit endogenous 
elongation indirectly, by affecting the previous activa- 
tion of the fatty acids to the acyI-CoAs by the micro- 
somal acyl-CoA synthetase. In this w~.y it is also pos- 
sible to obtain similar IC~0 values with the two pyridin 
nucleotides. 
To test the second hypothesis, we assayed the effect 
of  gemfibrozil on the exogenous elongation activity. By 
adding acyl-CoAs directly to the incubation medium, 
we were able to bypass the synthetase r action. Further, 
as Prasad et al. [13] have shown the existence of at least 
three different condensing enzymes for saturated, 
mona-unsaturated an  poly-unsatm'ated acyl-CoAs, re- 
spectively, we used paimitoyl-CoA, palmitoleoyl-CoA, 
and ~'-linolenoyl-CoA assubstrates, in order to evaluate 
the effect of gemfibrozil on the three different systems. 
in this set of assays, we used only NADPH as cofactor 
so as not to increase the complexity of the results: Nagi 
et al. [14] have shown the existence of two p-keto acyl- 
CoA reduetases, one dependent on NADPH and stimu- 
lated by the presence of BSA in the assay medium, and 
the other using NADH and being inhibited by the addi- 
tion of BSA. From the results shown in TAble I, and 
comparing these with the IC~0 value for NADPH-de- 
pendent endogenous elongation, we car' o~e that: (1) 
there is no significant difference among the four IC~0 
values, thus ruling out a possible aeyl-CoA synthetase 
inhibition by gemfibrozil. Furthermore. whe~, the inhi- 
bitory potency of gemfibrozil was assayed on palmitoyl- 
CoA synthetase activity (data not shown), an ICsa of 2.8 
mM was obtained, far from the ICs, values obtained for 
the elongation system: (2) gemfibrozil nhibits the three 
elongation activities with the same potency: this be- 
haviour is different from that of Ebselen, so far the only 
other organic ompound tested for in vitro inhibition of 
the three elongation systems, which showed a marked 
inhibitory preference for palmitoyI-CoA elongation [4]. 
Excluding the condensing enzyme, the other three 
enzymes of the elongation s~stem have enough activity 
to r,~lfii the maximal rate of elongation, even at 50% of 
their maximal activity (e.g. in fat-free diet- ",'d animals, 
activities are around 15 nmol/min/mg for NADPH de- 
pendent #-ketoacyl-CoA reductase [14], 80 nmol/min/ 
mg for #-hydroxyacyi-CoA dehydrase and 25 nmol/ 
rain/rag for trans-2-enoyI-CoA reductase [15]]. Thus. it 
seems possible to ascribe the inhibitory effect of gemfi- 
brazil to an inhibition of the condensing enzyme. 
Nevertheless, to test this hypothesis we assayed the 
effect of gemfibrozil on the condensation activity, again 
using the three different acyI-CoAs (16:0. 16:1 and r l 8:3 
CoA} As shown in Table 1. the IC~, values for con- 
densation activity are very similar, irrespective of the 
:,.cyi-CoA used as primer; moreover, there is no signili- 
c-tnt t_tif!'t:fq_n__c~_ h~_'~_W_P~__n_ i C_,;; VLll_tt~_S ¢orrespo_n_dLn_g to
e('rs,  ticm and condensation, confirming that gemli- 
broztl acls on elongation by inhibiting the condc~t~,ing 
step 
The ICso values of gemfibrozil obtained for en- 
dogenous and exogenous e;ongation are within the 
reported plasma concentration of the drug (0.1-0.8 
mM) [! 6] after its administration to laboratory animals 
or humans, Further, knowning that it has a tendency to 
accumulate in liver tissue [16], an effect of gemfibrozil 
on elongation activity after its administration i viva 
may be expected. To our knowledge, the in vitro or in 
viva effects of gemfibrozil on elongation activity have 
not been tested; there are only some contradictory data 
referring to another fibrie acid derivative, clofibric acid, 
Landriscina et al. [17J reported an inhibition of elonga- 
tion activity by ciofibric acid in vitro, although the in- 
hibitory potency was about 20-fold lower than that 
reported here for gemfibrozil. After semi-chronic ad- 
ministration in viva, either an induction [18] or an in- 
hibition [19] of palmitoyl-CoA elongation have been 
reported, although it should be pointed out that the 
dosage and duration of treatment were not exactly the 
same in these two different studies, As gemfibrozil 
seems to be a more powerful drug than clofibric acid, 
either in its effects on e~at ic  activities in vitro 
[20,21] or as a therapeutic hypolipemic agent [5], we are 
now conducting in viva experiments o ascertain the 
effect of gemfibrozil on elongation activP, y after semi- 
chronic administration. In this respect, it is interesting 
to note that Prasad and Cinti [22] have shown that 
feeding rats with di (2-eihylhexyl) phthalate (DEHP). 
another peroxisoma} inducer which is structurally unre- 
lated to gemfibrozi:, leads to induction of palmitoyl- 
CoA elongation activity. ~hile those of palmitoleoyi- 
CoA and r-linolenoyl-CoA decreased. 
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